Date: 2016-12-19
Type of information: Nomination
Compound:
Company: Innate Pharma (France)
Therapeutic area: Cancer - Oncology
Type agreement: nomination
Action mechanism:
Disease:
Details: * On December 19, 2016, Innate Pharma announced key leadership team and Board changes, including the appointment of Mondher Mahjoubi as Chairman of Innate Pharma’s Executive Board, succeeding Hervé Brailly who becomes Chairman of the Supervisory Board. The leadership team and Board changes will take effect on December 30th, 2016. Dr Mahjoubi, MD is currently Senior Vice President, Therapeutic Area Head-Oncology, Global Product and Portfolio Strategy, at AstraZeneca. He has been instrumental in driving the oncology strategy at AstraZeneca and beforehand at Genentech. Dr Mahjoubi is a medical oncologist trained at Institut Gustave Roussy (Paris-Villejuif). Dr Mahjoubi is bringing more than 20 years of experience working in clinical development, marketing and strategy in Europe and the USA for leading pharmaceutical companies in the field of oncology such as Aventis, Sanofi, Roche-Genentech, and AstraZeneca. Dr Hervé Brailly, PhD, who co-founded Innate Pharma 17 years ago, joins the Supervisory Board and will become its Chairman, succeeding Gilles Brisson who is stepping down after nine years in that position, and remains on the Board. Dr Philippe Pouletty, the longest serving member of the Board, will resign from the Board. As part of the governance changes, Laure-Hélène Mercier has been appointed as Chief Financial Officer. She was previously EVP, Finance, in charge of financial operations and, before that, Head of Investor Relations. Catherine Moukheibir, who has played a critical role as Senior Advisor for financial strategy, is leaving the Executive Board but will maintain her close links with the Company in an advisory position. Hervé Brailly wished that a new President of the Executive Board be appointed to take the Company to the next level. Since founding Innate Pharma, Hervé Brailly has overseen its development into one of Europe’s pre-eminent immuno-oncology companies, with three clinical-stage antibody candidates and a broad preclinical pipeline. The appointment of Mondher Mahjoubi and the additional governance changes are designed to support the Company’s evolution as it advances its key programs towards late-stage development. Mondher Mahjoubi’s strategic oversight, clinical expertise and commercial experience will prove invaluable to Innate Pharma as it lays the foundation to become a fully-integrated immuno-oncology company.
Financial terms:
Latest news:
